Method of purifying hemopexin using mixed-mode chromatography
AssigneeCSL Behring GmbH
InventorsKarl Beaumont MCCANN, Hal BRALEY, Chathuri WIJEKOON
Life of this patent
Estimating the term…
Abstract
Disclosed herein is a method of purifying proteins, in particular hemopexin, comprising passing a solution comprising hemopexin and other proteins through a mixed-mode cation exchange chromatography resin under conditions that promote selective binding of hemopexin to the resin, and eluting the bound hemopexin from the resin. The present disclosure also extends to compositions comprising purified hemopexin and uses thereof.
Claims73
A method of purifying hemopexin from a solution containing hemopexin and other proteins, the method comprising:
- (i) providing a solution comprising hemopexin and other proteins, wherein the solution comprises less than about 300 mM sodium chloride (NaCl);
- (ii) passing the solution of step (i) through a mixed-mode cation exchange chromatography resin under conditions that promote selective binding of hemopexin to the resin over binding of the other proteins to the resin;
- (iii) washing the resin after step (ii) to remove unbound proteins;
- (iv) eluting the hemopexin bound to the resin after step (iii);
- and
- (v) recovering the hemopexin eluted in step (iv).
A composition comprising a combination of any two or more of the characteristics selected from the group consisting of:
- (a) a hemopexin content of from about 95 mg/mL to about 110 mg/mL;
- (b) heme binding activity of from about 1000 μM to about 2000 μM;
- (c) heme specific binding activity of at least about 80% of total protein
- (d) a CD91 dissociation constant (KD) of from about 0.50 μM to about 2.0 μM;
- (e) a transferrin content of less than about 0.50 mg/mL;
- (f) an albumin content of less than about 0.05 mg/mL;
- (g) a haptoglobin content of less than about 0.05 mg/ml;
- (h) an Apo-A1 content of less than about 0.10 mg/mL;
- (i) a high molecular weight (HMW) hemopexin aggregate content of less than about 1.0% of total protein, as determined by size exclusion-high-performance liquid chromatography;
- (j) a hemopexin monomer content of at least about 90% of total protein, as determined by size exclusion-high-performance liquid chromatography;
- (k) a low molecular weight (LMW) impurity content of less than about 1.0% of total protein, as determined by size exclusion-high-performance liquid chromatography;
- (l) a hemopexin purity content of at least about 80% of total protein, as determined by reduced SDS-PAGE or as determined by non-reduced SDS-PAGE;
- (m) an isoelectric point (pI) of from about 5.0 to about 6.5, as determined by Capillary isoelectric focusing (cIEF);
- (n) a level of protease activity of less than about 5 nKat/L;
- (o) a level of prekallikrein activity of less than about 30 IU/mL;
- (p) a tri (n-butyl) phosphate (TnBP) content of less than about 10 μg/mL;
- and
- (q) a PS80 content of less than about 20 mg/mL.
A composition comprising a combination of any two or more of the characteristics selected from the group consisting of:
- (a) a hemopexin content of from about 95 mg/mL to about 110 mg/mL;
- (b) heme binding activity of from about 1600 μM to about 1800 μM;
- (c) heme specific binding activity of at least about 97% of total protein;
- (d) a CD91 dissociation constant (KD) of from about 1.10 μM to about 1.20 μM;
- (e) a transferrin content of less than about 0.25 mg/ml;
- (f) an albumin content of less than about 0.009 mg/mL;
- (g) a haptoglobin content of less than about 0.03 mg/ml;
- (h) an Apo-A1 content of less than about 0.06 mg/mL;
- (i) a high molecular weight (HMW) hemopexin aggregate content of less than about 0.6% of total protein;
- (j) a hemopexin monomer content of at least about 99% of total protein;
- (k) a low molecular weight (LMW) impurity content of less than about 0.4% of total protein;
- (l) a hemopexin purity content of at least about 88% of total protein;
- (m) an isoelectric point (pI) of from about 5.4 to about 6.3;
- (n) a level of protease activity of less than about 3 nKat/L;
- (o) a level of prekallikrein activity of less than about 20 IU/mL;
- (p) a tri (n-butyl) phosphate (TnBP) content of less than about 5 μg/mL;
- and
- (q) a PS80 content of less than about 18 mg/mL.
A composition comprising (i) a hemopexin content of from about 95 mg/mL to about 110 mg/mL, (ii) a hemopexin monomer content of at least about 99% of total protein, and (ii) a heme specific binding activity of at least about 97% of total protein.
Dependencies are inferred from the claim text.